A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 1, 2012, Pages 57-67

  Dranitsaris, George ^a   Ortega, Ana ^b   Lubbe, Martie S ^c   Truter, Ilse ^a  

^a NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c NORTH WEST UNIVERSITY   (South Africa)

Author keywords

chemotherapy; cost analysis; Drug pricing; Europe; value

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL STUDY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG WITHDRAWAL; EUROPE; GROSS NATIONAL PRODUCT; HEALTH CARE SYSTEM; HOSPITAL UTILIZATION; HUMAN; INTERVIEW; METASTASIS; METASTATIC COLORECTAL CANCER; NEUTROPENIA; NURSE; PHARMACIST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SPAIN;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; EUROPE; GROSS DOMESTIC PRODUCT; HUMANS; MODELS, ECONOMIC; NEOPLASM METASTASIS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPAIN; SURVIVAL ANALYSIS;

EID: 84857927361     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210390724     Document Type: Article

References (37)

1. World Health Organization. 'Cancer: the problem', http://www.who.int/nmh/ publications/fact-sheet-cancers-en.pdf (2008, accessed January 2010).
2. Wilking B, Jonsson N. A global comparison regarding patient access to cancer drugs. Ann Oncol. 2007 ; 18 (suppl 3). iii1-77
3. National Cancer Institute. 'Cancer Incidence: Surveillance Epidemiology and End Results (SEER)'. Washington, USA: National Cancer Institute, http://seer.cancer.gov/ (2010, accessed May 2010).
4. Stark CG. The burden of cancer in Europe and the availability of cancer drugs. EJHP Pract. 2009 ; 15: 20-23
5. Wilking B, Jonsson N A pan European comparison regarding patient access to cancer drugs. Stockholm: Karolinska Institute and Stockholm School of Economics ; 2005 :
6. Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs. 2007 ; 67: 2045-2075 (Pubitemid 47524565)
7. Moen MD, McKeage K, Plosker GL, Siddiqui MA. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs. 2007 ; 67: 299-320
8. Fojo T, Grandy C. How much is life worth: cetuximab, non small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009 ; 101: 1044-1048
9. Faden RR, Chalkidou K, Appleby J, et al. Expensive cancer drugs: a comparison between the United States and the United Kingdom. Milbank Q. 2009 ; 87: 789-819
10. Bach PB. Limits on medicare's ability to control rising spending on cancer drugs. New Engl J Med. 2009 ; 360: 626-633
11. Greece price cuts, http://www.nasdaq.com/aspx/company-newsstory.aspx? storyid=201005060849dowjonesdjonline000550 (2010, accessed May 2010).
12. 'Spain announces big drug price cuts, aiming for $1.6 million savings', http://www.thepharmaletter.com/file/95032/spain-announces-big-drug- price-cuts-aiming-for-16-billion-savings.html (2010, accessed May 2010).
13. FiercePharma. 'France joins European price cutting drive', http://www.fiercepharma.com/story/france-joins-european-price-cutting-drive/ 2010-06-02 (2010, accessed June 2010).
14. DaneL. 'Italy to cut price of select oncology drugs', http://www.firstwordplus.com/Fws.do?articleid=AEE577EE242444D4AD669A5E8A49F935 (2010, accessed June 2010).
15. 'Germany cuts drug industry's pricing power', http://www.chemanager- online.com/en/news-opinions/headlines/germany-cuts-drug-industrys-pricing-power (2010, accessed May 2010).
16. 'UK coalition government could end free drug pricing', http://www.forexpros.com/news/general-news/update-1-uk-coalition-govt-could-end- free-drug-pricing-139026 (2010, accessed June 2010).
17. Drummond MF, Mason AR. European perspective on the cost and cost effectiveness of cancer therapies. J Clin Oncol. 2007 ; 25: 191-195 (Pubitemid 350003033)
18. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992 ; 146: 473-481
19. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness. A case study in the challenges associated with 21st century cancer drug pricing. J Clin Oncol. 2009 ; 27: 2111-2113
20. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines in generalized cost effectiveness analysis. Health Econ. 2000 ; 9: 235-251 (Pubitemid 30248640)
21. Sarin R. Criteria for deciding cost effectiveness for expensive new anticancer agents. J Cancer Ther. 2008 ; 4: 1-2 (Pubitemid 351555993)
22. The World Fact Book. 'Central Intelligence Agency 2009', https://www.cia.gov/library/publications/the-world-factbook/rankorder/2004rank. html (2009, accessed November 2009).
23. Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy. 2008 ; 28: 23S - 30S
24. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther. 2007 ; 29: 2256-2267 (Pubitemid 350138568)
25. Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess. 2007 ; 11: 1-128, iii-iv
26. Price TJ, Tebbutt NC, Karapetis CS, et al. Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer. Clin Colorectal Cancer. 2010 ; 9: 8-14
27. Barugel ME, Vargas C, Krygier Waltier G. Metastatic colorectal cancer: recent advances in its clinical management. Expert Rev Anticancer Ther. 2009 ; 9: 1829-1847
28. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 ; 22: 229-237 (Pubitemid 41095086)
29. Engstrom PF. National Comprehensive Cancer Network. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy. 2008 ; 28 (11 Pt 2). 18S - 22S
30. Gomez-Batiste X, Tuca A, Corrales E, et al. Resource consumption and costs of palliative care services in Spain: a multicenter prospective study. J Pain Symptom Manage. 2006 ; 31: 522-532 (Pubitemid 43949119)
31. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis. 1987 ; 40: 593-600 (Pubitemid 17084806)
32. Gafni A. Alternatives to the QALY measure for economic evaluations. Support Care Cancer. 1997 ; 5: 105-111 (Pubitemid 27163450)
33. Leung P, Tanock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost utility analysis of chemotherapy using paclitaxel, docetaxel or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol. 1999 ; 17: 3082-3090 (Pubitemid 29470636)
34. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008 ; 26: 2013-2019
35. Orszag PR, Ellis P. The challenge of rising health care costs-a view from the Congressional Budget Office. N Engl J Med. 2007 ; 357: 1793-1795 (Pubitemid 350044798)
36. Jackevicius CA, Cox JL, Carreon D, et al. Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ. 2009 ; 181: E19-28
37. 'Prescribing caution: from wall street, a warning about cancer-drug prices', http://www.consumerwatchdog.org/patients/articles/?storyId=16076 (2007, accessed May 2010).